Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized as one of the most profitable dividend stocks, focusing on pharmaceuticals and medical devices after spinning off its consumer health unit into Kenvue [2][3] Financial Performance - In 2024, Johnson & Johnson invested approximately $17 billion in research and development (R&D) and distributed $11.8 billion in dividends, maintaining a quarterly dividend of $1.30 per share, resulting in a dividend yield of 2.77% as of October 6 [3] Business Strategy - The company has 26 products or platforms generating over $1 billion annually, which are crucial for its revenue and cash flow [2] - Johnson & Johnson aims to lead the oncology market with a target of $50 billion in sales, leveraging treatments like Darzalex and Carvykti [4] - The acquisition of Intra-Cellular Therapies for $14.6 billion introduced Caplyta, an antipsychotic drug expected to generate $5 billion annually [4] - Innovation in robotic surgery and cardiovascular care is central to the company's growth strategy in the medical technology sector [4]